Largest positions
| Issuer | Class | Value | Share |
|---|---|---|---|
| United Therapeutics Corp.Common | Common | $1,505,082,912 | 13.5% |
| Ascendis PharmaORDINARY SHARES | ORDINARY SHARES | $1,363,235,526 | 12.2% |
| Krystal Biotech Inc.Common | Common | $1,073,713,003 | 9.6% |
| Madrigal Pharmaceuticals Inc.Common | Common | $984,408,154 | 8.8% |
| Argenx SESponsored ADR | Sponsored ADR | $927,770,000 | 8.3% |
| Arrowhead Pharmaceuticals Inc.Common | Common | $925,591,288 | 8.3% |
| Kymera Therapeutics Inc.Common | Common | $857,129,238 | 7.7% |
| Revolution Medicines Inc.Common | Common | $430,182,160 | 3.9% |
| Cytokinetics Inc.Common | Common | $425,949,915 | 3.8% |
| Celcuity Inc.Common | Common | $355,708,000 | 3.2% |
| Structure Therapeutics Inc.SPONSORED ADS | SPONSORED ADS | $351,836,637 | 3.2% |
| Xenon Pharmaceuticals Inc.Common | Common | $348,746,620 | 3.1% |
| Definium Therapeutics Inc.Common | Common | $338,165,292 | 3.0% |
| Uniqure NVCommon | Common | $309,881,409 | 2.8% |
| Vera Therapeutics Inc.Common | Common | $245,612,034 | 2.2% |
| Taysha Gene Therapies Inc.Common | Common | $162,683,327 | 1.5% |
| Ocular Therapeutix Inc.Common | Common | $123,142,800 | 1.1% |
| Damora Therapeutics Inc.Common | Common | $98,395,830 | 0.9% |
| Hemab Therapeutics Hldgs Inc.Common | Common | $70,710,760 | 0.6% |
| GH Research PLCORDINARY SHARES | ORDINARY SHARES | $48,384,000 | 0.4% |
| Viridian Therapeutics Inc.Common | Common | $45,925,000 | 0.4% |
| Septerna Inc.Common | Common | $44,792,875 | 0.4% |
| Avalo TherapeuticsCommon | Common | $43,119,994 | 0.4% |
| Faeth Therapeutics Inc.COMMON | COMMON | $36,100,975 | 0.3% |
| Whitehawk Therapeutics Inc.Common | Common | $13,050,261 | 0.1% |
| Lexeo Therapeutics Inc.Common | Common | $6,932,175 | 0.1% |
- Class
- Common
- Share
- 13.5%
- Class
- ORDINARY SHARES
- Share
- 12.2%
- Class
- Common
- Share
- 9.6%
- Class
- Common
- Share
- 8.8%
- Class
- Sponsored ADR
- Share
- 8.3%
- Class
- Common
- Share
- 8.3%
- Class
- Common
- Share
- 7.7%
- Class
- Common
- Share
- 3.9%
- Class
- Common
- Share
- 3.8%
- Class
- Common
- Share
- 3.2%
- Class
- SPONSORED ADS
- Share
- 3.2%
- Class
- Common
- Share
- 3.1%
- Class
- Common
- Share
- 3.0%
- Class
- Common
- Share
- 2.8%
- Class
- Common
- Share
- 2.2%
- Class
- Common
- Share
- 1.5%
- Class
- Common
- Share
- 1.1%
- Class
- Common
- Share
- 0.9%
- Class
- Common
- Share
- 0.6%
- Class
- ORDINARY SHARES
- Share
- 0.4%
- Class
- Common
- Share
- 0.4%
- Class
- Common
- Share
- 0.4%
- Class
- Common
- Share
- 0.4%
- Class
- COMMON
- Share
- 0.3%
- Class
- Common
- Share
- 0.1%
- Class
- Common
- Share
- 0.1%
The share class is shown on a wider screen.
The 26 largest of 26 positions by value, with holdings of the same security combined. Share counts and quarter-on-quarter changes for each position are on EDGAR. View the full information table on EDGAR
This filing
- Form
- 13F-HR
- CIK
- 1633313
- File number
- 028-16573
- Options
- 0 call, 0 put
- In the 25 largest
- 99.9%
- Prior quarter
- $10,164,789,055 at 31 March 2026
- Positions opened
- 3
- Positions closed
- 9
Common questions
What are Avoro Capital Advisors’ 13F holdings worth?
$11,136,250,185 across 26 positions for the quarter ended 30 June 2026.
What is Avoro Capital Advisors’ largest 13F holding?
UNITED THERAPEUTICS CORP (Common) was the largest position at $1,505,082,912, or 13.5% of reported 13F value, as of 30 June 2026.
How concentrated is Avoro Capital Advisors’ 13F portfolio?
The ten largest positions accounted for 79.5% of reported value and the twenty-five largest for 99.9%, across 26 positions as of 30 June 2026.
Does Form 13F show everything Avoro Capital Advisors manages?
No. Form 13F covers only long positions in exchange-traded securities over which the manager has investment discretion, valued at quarter end. It excludes cash, most bonds, private funds, and any assets the firm does not have discretion over, so it is neither the firm's total assets nor any individual client's portfolio.
How often does Avoro Capital Advisors file its 13F?
Every quarter. Managers file within 45 days of each quarter's end, so the figures are a snapshot that changes between filings. This page shows the quarter ended 30 June 2026.
Answered from this filing and the prior quarter's.